The second-generation antipsychotics may not change the compromised neurobiology that underlies cognitive deficits.
Are the cognitive benefits claimed by manufacturers of second-generation antipsychotics an artificial result of repetitive practice in test conditions?
That's what a randomized trial of risperidone and olanzapine comparing cognitive improvements among first-episode schizophrenia patients and healthy controls suggests. Risperidone is marketed by Janssen Pharmaceutica as Risperdal, and olanzapine is marketed by Eli Lilly and Co. as Zyprexa.
The study, reported in the October Archives of General Psychiatry, found that the cognitive improvements among patients were consistent in magnitude with the "practice effects"—the effects of exposure, familiarity, and procedural learning that naturally occur in test conditions—seen in healthy patients.
READ MORE @ PSYCHIATRIC NEWS
Showing posts with label risperidone (Risperdal). Show all posts
Showing posts with label risperidone (Risperdal). Show all posts
Wednesday, November 21, 2007
Sunday, September 23, 2007
Risperidone Approved to Treat Schizophrenia in Children
FDA-requested pediatric studies provide valuable clinical evidence on the safety, efficacy, and dosage of antipsychotic drugs in children and adolescents.
The U.S. Food and Drug Administration (FDA) has approved the use of risperidone (Risperdal) in children and adolescents to treat schizophrenia and mania or mixed episodes of bipolar I disorder, making it the first atypical antipsychotic drug approved for either disorder in young patients.
The FDA announced last month that risperidone is approved for the treatment of schizophrenia in adolescents aged 13 to 17 and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents aged 10 to 17. Risperidone was approved in October 2006 for treating irritability associated with autistic disorders in children and adolescents aged 5 to 16 years.
READ MORE @ PSYCHIATRIC NEWS
The U.S. Food and Drug Administration (FDA) has approved the use of risperidone (Risperdal) in children and adolescents to treat schizophrenia and mania or mixed episodes of bipolar I disorder, making it the first atypical antipsychotic drug approved for either disorder in young patients.
The FDA announced last month that risperidone is approved for the treatment of schizophrenia in adolescents aged 13 to 17 and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents aged 10 to 17. Risperidone was approved in October 2006 for treating irritability associated with autistic disorders in children and adolescents aged 5 to 16 years.
READ MORE @ PSYCHIATRIC NEWS
Subscribe to:
Posts (Atom)
